Balyasny Asset Management LLC Vertex Pharmaceuticals Inc Put Options Transaction History

Balyasny Asset Management LLC

7 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	SELL	$460.0 - $505.78 $184,000 - $202,312	-400 Reduced 44.44%	500 $232,000
Q2 2024 Aug 14, 2024	BUY	$392.81 - $485.53 $353,529 - $436,977	900 New	900 $421,000
Q4 2023 Feb 14, 2024	BUY	$343.0 - $410.68 $274,400 - $328,544	800 New	800 $325,000
Q3 2022 Nov 14, 2022	BUY	$273.83 - $305.53 $3.53 Million - $3.94 Million	12,900 Added 330.77%	16,800 $4.86 Million
Q2 2022 Aug 15, 2022	SELL	$234.96 - $292.55 $6.13 Million - $7.64 Million	-26,100 Reduced 87.0%	3,900 $1.1 Million
Q3 2019 Nov 14, 2019	SELL	$166.23 - $187.09 $8.48 Million - $9.54 Million	-51,000 Reduced 62.96%	30,000 $5.08 Million
Q1 2019 May 15, 2019	BUY	$163.73 - $194.7 $13.3 Million - $15.8 Million	81,000 New	81,000 $14.9 Million

1,724

221M

1.58M

1.36M

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $102B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Balyasny Asset Management LLC with notifications on news.